Visugromab

• Target:

  PD-1/PD-L1|||TGF-beta/Smad

• Related Pathways:

  Apoptosis|||Stem Cells|||Cell Cycle/Checkpoint|||Immunology/Inflammation

• Purity:

  0.988

• Bioactivity:

  Visugromab (CTL-002) is a monoclonal antibody that targets and neutralises GDF-15. Visugromab exhibits synergistic anticancer activity with the anti-PD1 antibody Nivolumab, making it suitable for PD-1/PD-L1 recurrent/refractory metastatic solid tumours.

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  2556646-63-8